Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Rhythm Biosciences Ltd. ( (AU:RHY) ) has shared an announcement.
Rhythm Biosciences Ltd announced the issuance of 483,871 ordinary shares without disclosure under Part 6D.2 of the Corporations Act. The company confirmed compliance with relevant provisions of the Corporations Act and stated that there is no excluded information to disclose. This issuance supports Rhythm’s ongoing efforts to enhance its market position in the medical diagnostics industry, particularly in the early detection of colorectal cancer through its ColoSTAT® Test-Kit. The test, which measures specific protein biomarkers, offers an alternative to current screening programs and aims to reduce mortality rates and healthcare costs associated with colorectal cancer.
More about Rhythm Biosciences Ltd.
Rhythm Biosciences Ltd is an Australian medical diagnostics company focused on developing simple and affordable blood tests for early cancer detection. Founded in 2017 and headquartered in Melbourne, the company aims to improve patient outcomes and reduce the global burden of cancer through early detection. Rhythm collaborates with global partners for the commercialization and distribution of its diagnostic solutions.
Average Trading Volume: 231,399
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$18.84M
Find detailed analytics on RHY stock on TipRanks’ Stock Analysis page.